S Hallam1, F Ahmed2, N Gouvas2, S Pandey2, D Nicol2. 1. Worcestershire Acute Hospitals NHS Trust, Colorectal Surgery, Worcester, UK. Sallyelizabeth.hallam@nhs.net. 2. Worcestershire Acute Hospitals NHS Trust, Colorectal Surgery, Worcester, UK.
Abstract
BACKGROUND: Transanal TME (TaTME) was introduced to improve access to the pelvis in difficult cases (male sex, obesity and mid to low rectal cancers) and reduce the risk of anastomotic leak by avoiding cross stapling. In April 2018 the Norwegian hospital to whom all local; recurrences for rectal cancer are referred reported an unexpected rise in early multifocal local recurrences of 9.5% following TaTME compared with 3.4% following conventional TME leading to a nationwide moratorium on the procedure and ending, in an editorial published on the British Journal of Surgery in August 2020, by saying that other countries should consider the issue in the context of local practices and results. There are limited data concerning oncological outcomes of TaTME compared to conventional TME. The aim of this study was to report perioperative and oncological outcomes for patients with rectal cancer treated with TaTME in a high-volume, experienced UK centre. METHODS: From January 2015 to January 2020 consecutive patients with histologically confirmed rectal cancer having TaTME at Worcestershire Royal Hospital NHS were prospectively entered into an online international registry. Patients were followed according to local protocol with clinical examination, tumour markers, endoscopy and radiology. RESULTS: Seventy patients underwent TaTME for rectal cancer. The median distance of the tumour from the anorectal junction was 4 cm (IQR 2-5). The mesorectal margin was involved in 20 (1%) patients, all of whom received neoadjuvant chemoradiotherapy. Overall survival was 94% at a median follow-up of 15 months (IQR 9-31 months). Distant recurrence occurred in 12 (17%) of patients at a median of 14 months (IQR 10-17 months). The 18-month stoma-free survival rate was 66%. CONCLUSIONS: A local recurrence rate of 5.7% supports the oncological safety of TaTME for rectal cancer.
BACKGROUND: Transanal TME (TaTME) was introduced to improve access to the pelvis in difficult cases (male sex, obesity and mid to low rectal cancers) and reduce the risk of anastomotic leak by avoiding cross stapling. In April 2018 the Norwegian hospital to whom all local; recurrences for rectal cancer are referred reported an unexpected rise in early multifocal local recurrences of 9.5% following TaTME compared with 3.4% following conventional TME leading to a nationwide moratorium on the procedure and ending, in an editorial published on the British Journal of Surgery in August 2020, by saying that other countries should consider the issue in the context of local practices and results. There are limited data concerning oncological outcomes of TaTME compared to conventional TME. The aim of this study was to report perioperative and oncological outcomes for patients with rectal cancer treated with TaTME in a high-volume, experienced UK centre. METHODS: From January 2015 to January 2020 consecutive patients with histologically confirmed rectal cancer having TaTME at Worcestershire Royal Hospital NHS were prospectively entered into an online international registry. Patients were followed according to local protocol with clinical examination, tumour markers, endoscopy and radiology. RESULTS: Seventy patients underwent TaTME for rectal cancer. The median distance of the tumour from the anorectal junction was 4 cm (IQR 2-5). The mesorectal margin was involved in 20 (1%) patients, all of whom received neoadjuvant chemoradiotherapy. Overall survival was 94% at a median follow-up of 15 months (IQR 9-31 months). Distant recurrence occurred in 12 (17%) of patients at a median of 14 months (IQR 10-17 months). The 18-month stoma-free survival rate was 66%. CONCLUSIONS: A local recurrence rate of 5.7% supports the oncological safety of TaTME for rectal cancer.
Entities:
Keywords:
Local recurrence; Rectal cancer; Stoma; Transanal total mesorectal excision (TaTME)
Authors: Knut M Augestad; Deborah S Keller; Paul M Bakaki; Johnie Rose; Siran M Koroukian; Tom Øresland; Conor P Delaney Journal: Cancer Epidemiol Date: 2018-02-04 Impact factor: 2.984
Authors: N C Buchs; G Wynn; R Austin; M Penna; J M Findlay; A L A Bloemendaal; N J Mortensen; C Cunningham; O M Jones; R J Guy; R Hompes Journal: Colorectal Dis Date: 2016-12 Impact factor: 3.788
Authors: N S Fearnhead; A G Acheson; S R Brown; L Hancock; A Harikrishnan; S B Kelly; C A Maxwell-Armstrong; P M Sagar; S Siddiqi; C J Walsh; J M D Wheeler; J F Abercrombie Journal: Colorectal Dis Date: 2020-07 Impact factor: 3.788